4D Molecular Therapeutics, Inc. (FDMT) Operating cash flow 2019–2025
4D Molecular Therapeutics, Inc. (FDMT) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$109.1MFY2025 · since FY2019: -$36.7M → -$109.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$109.1M | +18.9% |
| FY2024 | -$134.6M | -77.6% |
| FY2023 | -$75.8M | +12.6% |
| FY2022 | -$86.7M | -25.4% |
| FY2021 | -$69.1M | -35.8% |
| FY2020 | -$50.9M | -38.7% |
| FY2019 | -$36.7M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More FDMT financial trends
FDMT RevenueFDMT Net incomeFDMT Net marginFDMT Gross profitFDMT Gross marginFDMT Operating incomeFDMT Operating marginFDMT Free cash flowFDMT Capital expendituresFDMT Return on equityFDMT Stock buybacksFDMT Dividends paidFDMT Total assetsFDMT Total liabilitiesFDMT Shareholders’ equityFDMT overview →